Opsidio, LLC
Opsidio, LLC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Opsidio, LLC.
Opsidio, LLC is a company.
Key people at Opsidio, LLC.
Key people at Opsidio, LLC.
Opsidio, LLC is a preclinical-to-clinical stage biotechnology company focused on developing novel biologic therapeutics, particularly monoclonal antibodies targeting the long form of Stem Cell Factor (SCF), to treat chronic inflammatory diseases such as fibrotic conditions, organ fibrosis, allergic diseases, remodeling diseases, respiratory diseases, and moderate-to-severe atopic dermatitis.[1][2][3][4] Its lead candidate, OpSCF, is in a Phase 2 study recruiting adults with moderate-to-severe atopic dermatitis, addressing unmet needs in patients suffering from the damaging effects of chronic inflammation that leads to severe outcomes like organ fibrosis.[2][4] Opsidio serves patients with these hard-to-treat conditions, solving the problem of uncontrolled chronic inflammation by breaking its cycle through targeted biologics, with early momentum shown by advancing to Phase 2 and ongoing recruitment.[2][4]
Opsidio was established in 2012 and is based in Bryn Mawr, Pennsylvania.[2] The company emerged from research by its scientific founders, who discovered that only the long form of Stem Cell Factor (SCF) is upregulated at sites of chronic inflammation—a finding known for decades but pivotal in directing Opsidio's focus on this target.[5] This insight led directly to the development of OpSCF and the company's formation.[5] Key leaders include CEO Martin Phillips, MD (30+ years in drug development, former CMO of venture-funded biotechs), CSO Nicholas Lukacs, PhD (University of Michigan professor with 25+ years of research, >350 papers), and COO/CFO John Oates (20+ years in life sciences operations and early-stage growth).[5] Early traction stems from this foundational science, evolving into active clinical programs like the Phase 2 OpSCF trial.[2][4][5]
Opsidio rides the wave of precision biologics in immunology, capitalizing on growing recognition of isoform-specific targets like long-form SCF to address limitations in existing therapies for fibrosis and atopic dermatitis.[1][5] Timing is ideal amid surging demand for atopic dermatitis treatments—post-JAK inhibitor approvals and amid biologics expansion—fueled by market forces like rising chronic disease prevalence and biologics' projected dominance in inflammation markets.[2][4] By advancing OpSCF to Phase 2, Opsidio influences the ecosystem through novel SCF modulation, potentially setting new standards for fibrotic disease intervention and contributing to the shift toward site-specific anti-inflammatories.[2][5]
Opsidio's near-term path hinges on Phase 2 OpSCF data readout, which could validate SCF targeting and propel partnerships or funding in a hot inflammation space. Trends like AI-driven target discovery and combo therapies with existing biologics will shape its trajectory, amplifying its niche in fibrosis-atopic overlap. Influence may evolve from preclinical innovator to clinical contender, potentially reshaping treatment paradigms for chronic inflammation if Phase 2 succeeds—reinforcing its mission to deliver remedies where need is greatest.[2][4][5]
